Immunicum - ilixadencel in MERECA Phase II - results soon ! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: loparn	2/4/2020 5:23:19 AM
	of 17

Immunicum's new abstract satisfies the stock market today. finance.yahoo.com It is just one completely new item regarding the Phase II MERECA study in metastatic renal cell cancer (and shorters getting nervous) that is the cause of this : "Confirmed ORR was 42.2 % (19/45) versus 24.0% (6/25)" Along with 4 other already communicated positive tumor response end points and very good OS data known since Sept 25 2019, there are increased expectations before new survival data from MERECA that will be reported on Feb 6, when Immunicum's abstract has been elected for oral presentation. meetinglibrary.asco.org ml-eu.globenewswire.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next